Geert R D'Haens

Summary

Affiliation: Katholieke Universiteit Leuven
Country: Belgium

Publications

  1. ncbi Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
    G D'Haens
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 116:1029-34. 1999
  2. ncbi Infliximab (Remicade), a new biological treatment for Crohn's disease
    G R D'Haens
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Ital J Gastroenterol Hepatol 31:519-20. 1999
  3. ncbi Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis
    G D'Haens
    Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 120:1323-9. 2001
  4. ncbi Anti-TNF therapy for Crohn's disease
    Geert D'Haens
    Department of Gastroenterology at the University Hospital Gasthuisberg, Leuven, Belgium
    Curr Pharm Des 9:289-94. 2003
  5. ncbi Infliximab as disease-modifying therapy
    Geert R D'Haens
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Eur J Gastroenterol Hepatol 15:233-7. 2003
  6. ncbi Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial
    Geert R D'Haens
    Department of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Gastroenterology 135:1123-9. 2008

Detail Information

Publications6

  1. ncbi Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
    G D'Haens
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 116:1029-34. 1999
    ..Tumor necrosis factor (TNF) is a pivotal cytokine in intestinal inflammation. Controlled trials using a chimeric anti-TNF antibody (infliximab) have shown its efficacy in refractory Crohn's disease...
  2. ncbi Infliximab (Remicade), a new biological treatment for Crohn's disease
    G R D'Haens
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Ital J Gastroenterol Hepatol 31:519-20. 1999
    ..In conclusion, infliximab appears to offer a promising novel therapeutic agent for refractory and fistulizing Crohn's disease. Long-term risks and benefits remain to be determined...
  3. ncbi Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis
    G D'Haens
    Department of Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 120:1323-9. 2001
    ..We investigated the effects of intravenous (IV) cyclosporine as single IV therapy (without glucocorticosteroids) for severe UC and compared these with the response to glucocorticosteroids...
  4. ncbi Anti-TNF therapy for Crohn's disease
    Geert D'Haens
    Department of Gastroenterology at the University Hospital Gasthuisberg, Leuven, Belgium
    Curr Pharm Des 9:289-94. 2003
    ..Expected and unexpected safety toxicity data should caution clinicians to a certain extent against too liberal use of these agents interfering with very basic physiological events...
  5. ncbi Infliximab as disease-modifying therapy
    Geert R D'Haens
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Eur J Gastroenterol Hepatol 15:233-7. 2003
    ..Appropriate indications for using infliximab and growing experience with safety aspects have made this treatment a highly valuable tool in the management of Crohn's disease...
  6. ncbi Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial
    Geert R D'Haens
    Department of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Gastroenterology 135:1123-9. 2008
    ..Goal: We sought to examine whether metronidazole for 3 months together with azathioprine (AZA) for 12 months is superior to metronidazole alone to reduce recurrence of postoperative CD in "high-risk" patients...